Nicholson, Bethany
Goodman, Rupert
Day, James
Worth, Austen
Carpenter, Ben
Sandford, Kit
Morris, Emma C.
Burns, Siobhan O.
Ridout, Deborah
Titman, Penny
Campbell, Mari http://orcid.org/0000-0001-5009-8307
Article History
Received: 16 November 2021
Accepted: 1 May 2022
First Online: 20 June 2022
Declarations
:
: The study was conducted with approval from WALES REC 6 (Ref: CitationRef removed/WA/0147).
: Informed consent was obtained from all participants recruited into the study.
: All authors agreed to this publication.
: MC has received research grants from the National Institute of Health Research, the Royal Free Charity, Primary Immunodeficiency Association and PIDUK, financial support to attend symposia from CSL Behring, Grifols, BPL and Biotest, a service development grant from CSL Behring and honoraria for speaking engagements from Shire, Takeda & HAEUK. ECM has received support from the UKRI, the European Union, National Institute of Health Research (NIHR) UCLH Biomedical Research Centre, has done ad hoc consultancy for Orchard Therapeutics Ltd, GSK and is a Scientific Founder of Quell Therapeutics Ltd. SOB has received grant support from the European Union, National Institute of Health Research, UCLH and GOSH/ICH Biomedical Research Centers and CSL Behring and personal fees or travel expenses from Immunodeficiency Canada/IAACI, CSL Behring, Baxalta US Inc and Biotest. AW is an Advisory board consultant for SA Novimmune and Orchard Therapeutics.